Nurix Therapeutics, Inc.
NRIX
$15.60
-$0.13-0.83%
NASDAQ
| 11/30/2025 | 08/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 71.99% | -82.08% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 71.99% | -82.08% | |||
| Cost of Revenue | -3.59% | 10.27% | |||
| Gross Profit | 11.22% | -129.81% | |||
| SG&A Expenses | 3.72% | -7.86% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -2.63% | 7.47% | |||
| Operating Income | 9.07% | -89.12% | |||
| Income Before Tax | 9.49% | -102.37% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 9.49% | -98.83% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 9.49% | -98.83% | |||
| EBIT | 9.07% | -89.12% | |||
| EBITDA | 8.71% | -93.92% | |||
| EPS Basic | 19.89% | -98.17% | |||
| Normalized Basic EPS | 19.90% | -101.70% | |||
| EPS Diluted | 19.89% | -98.17% | |||
| Normalized Diluted EPS | 19.90% | -101.70% | |||
| Average Basic Shares Outstanding | 12.99% | 0.33% | |||
| Average Diluted Shares Outstanding | 12.99% | 0.33% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||